TSBX NASDAQ
Turnstone Biologics Corp.
1W: +1.1%
1M: -3.6%
3M: +4.4%
1Y: -83.6%
$0.35
Last traded 2025-08-11 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$8.2M
52W Range0.29-2.2614
Volume283,774
Avg Volume404,925
Beta1.37
Dividend—
Analyst Ratings
Company Info
CEOSammy J. Farah
Employees14
SectorHealthcare
IndustryBiotechnology
IPO Date2023-07-21
Websiteturnstonebio.com
9310 Athena Circle
LA Jolla, CA 92037
US
LA Jolla, CA 92037
US
347-897-5988
About Turnstone Biologics Corp.
Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, and uveal melanoma, as well as an investigator sponsored trial to treat cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.
Latest News
No recent news
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | U-Tender | 3,099,265 | $0.34 | 2025-08-08 |
| Versant Ventures V, | U-Tender | 274,990 | $0.34 | 2025-08-08 |
| Jerel Davis | U-Tender | 82,006 | $0.34 | 2025-08-08 |
| Gupta Rishi | U-Tender | 3,099,265 | $0.34 | 2025-08-08 |
| Rajangam Kanya | A-Award | 12,770 | $2.69 | 2024-06-03 |